Research shows long-term use of opioids is often ineffective in treating chronic pain, says Barry Meier, New York Times reporter.
There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.
Stanley Crooke, Isis Pharmaceuticals chairman & CEO, discusses his company's strategic new partnership in the treatment of neurological disorders using antisense therapy.
After two decades of research, a treatment that slows or reverses the progression of Alzheimer's has proved elusive. The aging of the global population makes the need more urgent.
As resources move to other areas, cardiologists fear the battle against heart disease could stall after advances marked by critical drugs to lower cholesterol and blood pressure.
After news that U.S. missile strikes in Syria could come "as early as Thursday," Cramer suggested some sectors that may help investors protect portfolios amid geopolitical turmoil.
FINRA warned Tuesday that scammers have been targeting investors attempting to tap into the growing U.S. marijuana industry.
Aline Plançon, assistant director of Interpol's medical products counterfeiting and pharmaceutical crime sub-directorate, tells CNBC that the largest fake pharmaceutical markets are in Asia and Latin America.
Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk, the latest evidence of a widening investigation into Western drugmakers.
Leonard Schleifer, Regeneron Pharmaceuticals president and CEO, breaks down the company's better-than-expected earnings, and positive results from its phase three trials of a drug designed to improve vision in patients with diabetic macular edema.
Alex Rodriguez was suspended through 2014 and All-Stars Nelson Cruz, Jhonny Peralta and Everth Cabrera were banned 50 games apiece Monday when Major League Baseball disciplined 13 players in a drug case.
Procter & Gamble posts earnings of 79 cents a share vs. 77 cents estimate.
Barbara Ryan, FTI Consulting, breaks down the second quarter numbers on Pfizer and Merck and provides an outlook on which companies have the best drugs in the pipeline.
Merck reported second-quarter earnings on Tuesday that exceeded analysts' expectations, yet revenues fell on weak drug sales.
Pfizer reported earnings slightly ahead of forecasts, as the largest U.S. drugmaker lines up a business split that could lead to the spin-off of its generics division.
Regardless of what narrative may ultimately prove to best explain GSK's current problems in China, doing business in the sector for multinationals will never be the same.
Both Pfizer and Merck are expected to report double-digit declines in top- and bottom-line growth when they announce earnings Tuesday.
Barbara Ryan, FTI Consulting, provides a preview of Pfizer and Merck's earnings, and discusses how both pharma giants have improved shareholder value through M&A.
U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatment and tax savings from being domiciled in Ireland.
In a recent report, researchers found that blood pressure medication also functions to provide measurable relief for patients experiencing worsening Alzheimer's symptoms.